Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Personalis, Inc.
< Previous
1
2
3
4
Next >
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 16, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers
August 15, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
August 04, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports Second Quarter 2022 Financial Results
August 03, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Files Patent Infringement Lawsuit Against Foresight Diagnostics
August 02, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Announce Second Quarter 2022 Financial Results
July 20, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease
July 12, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports First Quarter 2022 Financial Results
May 04, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present at Upcoming Investor Conferences
April 28, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales
April 21, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Announce First Quarter 2022 Financial Results
April 20, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene
April 12, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ Platform
April 12, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022
April 11, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present at the 21st Annual Needham Virtual Healthcare Conference
March 31, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors
March 24, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022
March 23, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present at the Cowen 42nd Annual Health Care Conference
February 23, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection
February 15, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Announce Fourth Quarter and Full-Year Financial Results
February 10, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 01, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
January 06, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Participate in the 24th Annual Needham Virtual Growth Conference
December 28, 2021
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity
December 16, 2021
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference
November 18, 2021
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Named to Inc.'s 2021 Best-Led Companies List
November 12, 2021
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present New Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
November 11, 2021
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports Third Quarter 2021 Financial Results
November 04, 2021
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Updates to NeXT Platform™ Incorporating Additional Key Profiling Capabilities for Advancing Oncology Biomarkers
November 02, 2021
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.